Precision risk-based screening might maximize benefit and minimize harm. Read more about Precision risk-based screening might maximize benefit and minimize harm.
Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Read more about Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Read more about Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Surgical oncology for gliomas: the state of the art. Read more about Surgical oncology for gliomas: the state of the art.
Cholangiocarcinoma - evolving concepts and therapeutic strategies. Read more about Cholangiocarcinoma - evolving concepts and therapeutic strategies.
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Read more about Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Head and neck cancer in 2016: A watershed year for improvements in treatment? Read more about Head and neck cancer in 2016: A watershed year for improvements in treatment?
Translational and clinical implications of the genetic landscape of prostate cancer. Read more about Translational and clinical implications of the genetic landscape of prostate cancer.
Population-based screening for cancer: hope and hype. Read more about Population-based screening for cancer: hope and hype.
Emerging biomarkers in head and neck cancer in the era of genomics. Read more about Emerging biomarkers in head and neck cancer in the era of genomics.
